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ABSTRACT
Stem cell research has attracted much public and biomedical
anticipation centred on the possibility of using stem cells to
treat various diseases and conditions, but the number of
evidence-based therapies is currently limited. Numerous
commercial direct-to-consumer (DTC) businesses are
nonetheless marketing experimental stem cell therapies
online for myriad medical conditions and aesthetic
ailments, which has attracted critique due to safety and
eﬃcacy concerns. Existing research has largely focused on
the problem of unproven therapies and regulatory
pathways for addressing it. The proliferation of these
experimental products must also be examined, however, in
the broader socio-technological context of consumer
culture and changing practices of knowledge-making in the
digital era. DTC stem cell therapies have emerged as a new
biomedical ‘lifestyle’ product that blurs the boundaries
between ‘science,’ ‘medicine,’ and ‘consumer culture.’ In
using, conceptualising and marketing stem cells,
commercial businesses build on and commercially co-opt
alternative epistemic and ontological frames that challenge
scientiﬁc medicine. They advance promissory narratives
about their potential that tap on cultural aspirations around
the future of medicine and health. This is key, not only for
understanding how and why these therapies have
proliferated but also in conceptualising what the ‘problem’






Translational stem cell science has attracted signiﬁcant interest, controversy, and
anticipation centred around the regenerative potential of stem cells and their
utilisation to treat myriad diseases and ailments. Yet, apart from a small
number of evidence-based therapies, evidence for the eﬀectiveness and safety
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of clinical applications for stem cells is currently insuﬃcient or in the pre-clinical
stage. Despite this, recent years have witnessed the global proliferation of com-
mercial businesses providing experimental stem cell therapies that have not
undergone clinical trials but are nonetheless oﬀered by private healthcare provi-
ders1 who advertise them online (Berger et al., 2016; Turner and Knoepﬂer,
2016). The emergence and success of commercial stem cell therapies is facilitated
by digital technologies, which enable the creation and sharing of information
and knowledge in an unprecedented scale. Healthcare businesses leverage
these technologies, including major internet platforms such as Google, to
market their products directly to consumers.
The emergence and abundance of stem cell businesses has attracted wide-
spread condemnation from mainstream medical authorities who have issued
warnings about the dangers of experimental stem cell therapies. Critical com-
mentaries calling for stronger regulation and customer protection around
such therapies have multiplied (e.g. Regenberg et al., 2009; ISSCR, 2010;
McLean et al., 2015; Lysaght et al., 2017; Sipp, 2017). The success of commercial
stem cell businesses suggests that large numbers of health consumers are none-
theless choosing to undergo experimental stem cell interventions marketed
online, directly contravening healthcare authorities’ advice. This phenomenon
takes place via an evolving digital landscape where diﬀerent claims, forms of
knowledge and expertise are in open competition with orthodox scientiﬁc
frames of knowledge production.
The proliferation of commercial stem cell businesses has also attracted much
commentary and research (e.g. Petersen and Seear, 2011; Petersen et al., 2015;
Salter et al., 2017; Sipp, 2017; Murdoch et al., 2018). This has included eﬀorts
to document the number and distribution of the businesses and types of treat-
ments marketed in the USA (Turner and Knoepﬂer, 2016) and across the
globe (Berger et al., 2016). Existing research has primarily focused on document-
ing and analysing the scope of the problem, where the ‘problem’ is usually taken
to be inadequate safety, eﬃcacy, and lax regulation of experimental therapies.
The key concern is potential and actual exploitation of vulnerable patients
who choose to undergo and pay for therapies even though the therapies’ eﬀec-
tiveness and safety is not evidenced, and the knock-on eﬀects on aftercare this
may have for healthcare infrastructures.
A closer examination of the websites where stem cell therapies are advertised,
however, highlights that the broader discursive and epistemic frameworks that
are mobilised by businesses marketing experimental stem cell interventions
are important in making sense of this growing market. These frameworks,
which concern the nature of knowledge and how it is produced, also relate to
the socio-medical and techno-scientiﬁc context of digital media, which is key
for understanding how the businesses operate. A clue towards this end
emerged from Berger et al. (2016) and Turner and Knoepﬂer’s (2016) research
including on the types of stem cell therapies marketed by commercial businesses.
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Their research indicates that a large proportion of the stem cell therapy market is
focused on ‘cosmetic’ or ‘aesthetic’ therapies, rather than on what have been
deﬁned as ‘medical’ treatments. While this does not distract from the impor-
tance of analysing the safety and eﬃcacy of experimental medical therapies, it
is interesting that this characteristic of the market has attracted little exploration
and scrutiny.2
We oﬀer a case-study of the UK-based commercial direct-to-consumer
(DTC) online market of experimental stem cell therapies, in order to explore
the following questions: how are ‘stem cells’ conceptualised and represented
to consumers? What epistemic frames guide these conceptualisations and rep-
resentations, and how do they ﬁt within the current landscape of science, medi-
cine, and consumer culture?
Our aims are twofold: ﬁrstly, while we map the scope of the UK market, our
objective is less to document the number and distribution of the businesses and
more to use this mapping as background for examining how the digitally
mediated market itself oﬀers an emerging alternative discursive and epistemic
sphere to conventional evidence-based medicine. Whereas existing research
has primarily taken the problem around commercial stem cell therapies to be
insuﬃcient regulation, safety, eﬃcacy, and consumer exploitation, we aim to
look beyond this conceptualisation of the problem. We aim to shed new light
on the techno-scientiﬁc and medico-cultural context within which the therapies
have been commercialised. This is because the currently dominant framings of
the problem can have the eﬀect of constraining the scope of analysis in ways that
limit our ability to properly account for the context that foregrounds how these
therapies are marketed.
Secondly, we aim to contribute to existing STS literature on the nature and
implications of knowledge-making in the digital era. We do this by exploring
how digital environments mediate the co-existence of plural knowledges and
the emergence as well as commercial co-optation of alternative epistemic frame-
works that challenge scientiﬁc medicine. The epistemic frames used by commer-
cial stem cell therapy businesses exemplify a blurring of the boundaries between
medicine and consumer culture. Experimental DTC stem cell therapies can be
understood as a new kind of biomedical ‘lifestyle’ product that represents the
fragmentation of conventional scientiﬁc authority. This perspective also broad-
ens the scope of current discussions and debate around DTC stem cell therapies,
as it oﬀers a contextualising angle that should be accounted for in developing
responses to the proliferation of experimental stem cell therapies.
Analytical Perspectives: Medical Knowledge (Making) in the
Digital Era
Digital technologies are changing how patients and consumers use, access and
interpret medical information, and how they communicate about and purchase
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healthcare services and products (Lupton, 2013; Sosnowy, 2014; Saukko, 2018).
Digital media have exponentially expanded individuals’ access to both conven-
tional and alternative information about medicine and health. The eﬀect is that
medical knowledge (including the production and critique of this knowledge)
can no longer be seen as the exclusive purview of trained medical and healthcare
professionals. The plural and easily accessible information sources and knowl-
edge claims that co-exist in online environments have made medical infor-
mation open to re-interpretation and re-framing in unprecedented ways.
Individuals can (re)search and evaluate this information for themselves while
commercial healthcare service providers have access to new ways of marketing
their products via DTC advertising, which can bypass mainstream medical
information channels. This includes the unprecedented capacity of commercial
businesses to distribute information about emerging but not (yet) clinically
proven therapies, including experimental stem cell interventions.
Concurrently and relatedly, it has been argued that the ‘digital era’ in which
we increasingly live is characterised by growing scepticism towards conventional
scientiﬁc medicine. Top-down forms of medical knowledge production and
hierarchical or clinician-centred models of the clinical encounter (where
medical professionals are accredited with epistemic superiority) are becoming
increasingly contested (Lupton, 2012). This is reﬂected in the drive towards
patient-centred healthcare and emergence of phenomena like ‘citizen science’
(see Prainsack, 2014). These suggest that actors outside the academy and the
medical profession, including patients and consumers, occupy increasingly
active roles in the production and interpretation of scientiﬁc and health knowl-
edge. They can also construct alternative understandings of their own health
(Neﬀ and Nafus, 2016; Saukko, 2018).
The emergence of DTC medicine (including stem cell therapies) is a related
phenomenon. It mirrors the fragmentation of top-down forms of medical
knowledge-making and pluralistic modes of health and knowledge in the
digital era, but it also represents the commercialisation of knowledge pluralism.
The online search technologies (see Mager, 2012) that consumers primarily use
to ﬁnd and access DTC services are inscribed with capitalist power dynamics:
search engines including Google use tactics like user proﬁling to catalogue infor-
mation about the interests and desires of individuals and groups based on their
online histories and behaviours. This can in turn be commodiﬁed by ﬁrst selling
the proﬁles to commercial and advertising businesses and then marketing them
back to consumers via user-targeted advertising (Mager, 2012). Relatedly, the
parameters of the digital environments in which DTC medicine operates facili-
tate the commodiﬁcation of patients’ and consumers’ interests and hopes
(Saukko, 2018) including around experimental stem cell interventions (Petersen
and Seear, 2011).
As others have analysed, health consumers choosing to undergo experimental
DTC stem cell therapies often articulate their decision in terms of the hope that
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these interventions are perceived to carry for living a healthier or better life (e.g.
Rachul, 2011; Petersen et al., 2013, 2015). DTC stem cell businesses in turn
harness this hope in the strategies they use to market their products (Petersen
and Seear, 2011). This is connected with the future-oriented nature of the
stem cell therapy market: experimental stem cell interventions, like many
other new and emerging biotechnologies (see e.g. Brown et al., 2000; Moreira
and Palladino, 2005; Broer and Pickersgill, 2015), are characterised by expec-
tations about a better, healthier future. This future is seen to be enabled by a
new wave of medicine – expectations that are attached to new biotechnologies
are their future promise. These ‘promissory narratives’ (see e.g. Brown et al.,
2000) tend to utilise a rhetoric of hope whereby scientiﬁc research and exper-
imentation are justiﬁed by the promise of new treatments or miraculous
medical innovations (Moreira and Palladino, 2005).
The discourses and metaphors that DTC stem cell businesses mobilise to
market their products not only enact promissory narratives but also capitalise
on these narratives. They position health consumers as agents who can contrib-
ute to realising better therapeutic futures by investing in experimental (stem cell)
medicine today. Indeed, much social analysis of DTC medicine in its many
manifestations (e.g. Saukko et al., 2010; Dumit, 2012; Prainsack, 2014) points
towards a tension between patient and consumer empowerment rhetoric pro-
moted by DTC businesses and the businesses’ commercial interests.
Notably, Saukko (2018) has argued that commercially promoting medical
knowledge as open, not only to consumers’ contributions but also to (re-
)interpretation by consumers themselves conﬁgures this knowledge as ‘tenta-
tive.’ This is intertwined with the promotion of commercial digital healthcare
as more participatory or empowering than traditional healthcare models.
Instead of being framed as ﬁxed facts that are disseminated by scientiﬁc
experts who know better, medical information is re-conﬁgured as ‘in-formation’
in ways that enable dynamism in how it is understood and mobilised by individ-
uals. This is related to the changing status of facts and expertise in contemporary
digital societies: it has been argued that it can no longer be presumed that
publics’ respect for facts can be secured via the authority of experts legitimated
by agencies outside the public domain (Marres, 2018).
Contextualised by the changing dynamics of knowledge (making) in the digital
era, Saukko et al. (2010) have also argued that we are witnessing the emergence of
a new, digitallymediated socialmarketing space for biomedical ‘lifestyle’ products
which blur the space between medicine and consumer culture. The emergence of
these ambiguously situated products vis-a-vismedical and consumer goods is part
of broader phenomena throughwhich the conventional boundaries of science and
medicine are being re-drawn (Nowotny et al., 2001). Indeed, Saukko et al. (2010)
argue the emergence of these ‘hybrid’medico-cultural entities and the transform-
ation of the boundaries of what does or is taken to constitute science andmedicine
is symptomatic of our current historical times.
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In what follows, we will build on and contribute to existing analyses of knowl-
edge-making, commercialised (re)interpretation and (promissory) uses of
science in the digital era. We do this by focusing on stem cell businesses and
how they conﬁgure (the meaning and value of) their products through their
marketing strategies and portrayals. In particular, we build on Saukko et al.
(2010) to argue that commercial experimental stem cell therapies exemplify
the blurring of science, medicine, and consumer culture in ways that have impli-
cations beyond the safety and eﬃcacy problem of commercial stem cell
interventions.
The Landscape: Stem Cell-based Therapies in the UK and Beyond
While there has been signiﬁcant research investment in clinical applications for
stem cells – indeed, the UK Clinical Trials Gateway (UKCTG, 2018) contained
191 recruiting stem cell therapy trials at the time of writing – the vast majority of
proposed therapies are not supported by existing scientiﬁc evidence (Sipp, 2017).
In the UK, the National Health Service (NHS) largely sets the standards for
accepted medical treatments. It only oﬀers haematopoietic stem cell transplants
(derived from bone marrow or blood) as part of some cancer and blood disorder
treatments (e.g. leukaemia, lymphoma, and sickle cell anaemia). Recently, some
NHS hospitals have also begun to oﬀer haematopoietic stem cell transplants for
some conditions. These include relapsing-remitting Multiple Sclerosis failing
alternate approved therapy, albeit with strict treatment access inclusion and
exclusion criteria (NHS, 2017). These new uses apply well-established treatment
protocols in bone marrow and blood transplantation rather than new treatment
protocols.
Commercial businesses, however, oﬀer stem cell therapies for a variety of dis-
eases and aﬄictions that are not oﬀered (nor approved) by public and main-
stream healthcare providers and authorities. These therapies have often not
undergone clinical trials nor are they derived from the well-established treat-
ments, but they are nevertheless accessible and marketed directly to customers
via digital platforms. Digital media provide commercial healthcare providers
with a marketing avenue and customer base that seems willing and able to
pay for and even travel beyond borders to receive experimental stem cell thera-
pies. Indeed, ‘stem cell tourists’ have received much commentary, especially
from the perspectives of medical tourism and healthcare commercialisation in
the global context (e.g. Song, 2010; Petersen et al., 2013; Petersen et al., 2017).
Due to scarce evidence for most stem cell therapies’ eﬀectiveness and safety
(and, in some cases, implausible scientiﬁc basis), mainstream healthcare auth-
orities working within evidence-based epistemologies have widely condemned
these therapies and the businesses providing them. The consequence has been
that boundaries have been drawn between ‘legitimate’ and ‘illegitimate’ or
‘proven’ and ‘unproven’ therapies, where the boundary has primarily focused
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on the existence and lack thereof of evidence from clinical trials (Petersen et al.,
2015; Sleeboom-Faulkner, 2016). Indeed, the NHS in collaboration with other
healthcare authorities including the UK Department of Health have issued
warnings about ‘rogue clinics’ oﬀering ‘risky stem cell treatments’:
stem cell clinics around the world are exploiting patients…Despite the experimental
state of many stem cell therapies, they are being sold over the internet directly to
patients.… There is concern these companies are putting patients with often very
serious and terminal conditions at further risk with untested treatments, while extract-
ing substantial payment from them. (NHS, 2008).
The International Society for Stem Cell Research (ISSCR) has also issued guide-
lines for prospective stem cell patients, instructing them to evaluate stem cell
therapy providers against conventional evidence-based scientiﬁc criteria (SCR,
2008). The ISSCR additionally published a report condemning unproven stem
cell treatments, urging for their stronger national and international regulation
(ISSCR, 2010).
Until recently, discussions around these therapies focused on lenient regulat-
ory systems in middle-income countries including China and India. These were
taken to be fuelling a movement of stem cell tourists from Western countries to
emerging economies in search of alternative therapies not available in more
restrictive high-income jurisdictions (Kiatpongsan and Sipp, 2009). A key regu-
latory issue for the global stem cell therapy market is that much of it operates
outside orthodox (i.e. evidence-based, marketing approvals-compliant) research
and innovation governance (Salter et al., 2017). Mainstream scientiﬁc inﬂuen-
cers have argued that uninformed patients and health consumers may be
exploited if appropriate regulatory oversight is not imposed and implemented
for so-called unproven stem cell interventions. Stronger regulation and over-
sight, they argue, are needed to protect patients’ and consumers’ health, mitigate
risks, and safeguard informed choice (Regenberg et al., 2009; ISSCR, 2010;
McLean et al., 2015; Lysaght et al., 2017).
Yet, experimental stem cell therapies have become increasingly commercially
available also in high-income countries including the UK, which indicates that
their global proliferation cannot be reduced to weak regulation (alone)
(Lysaght et al., 2015). Berger et al. (2016) have shown that the marketing of
stem cell-based therapies is now skewed towards businesses in high-income
economies with relatively strong regulatory systems. The largest distribution
located in the USA. Indeed, Turner and Knoepﬂer (2016) identiﬁed 351 US-
based businesses. Salter et al. (2017) have argued that emphasis on enforcing
regulation over predatory clinics, combined with the presumption of a uni-
formed customer-base, fails to appropriately account for the complexities of
the market.
Mainstream medical and scientiﬁc authorities often take for granted the clini-
cal trial process that is required to establish the safety and eﬃcacy of clinical
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applications. This process is, however, time consuming and frustrates demand
for the speedy development of, and access to, therapies for conditions for
which no evidence-based interventions currently exist (Salter et al., 2017). Com-
mercial healthcare providers ﬁll the gap between demand and therapy options,
including by moving from basic research directly to clinical application.
Relatedly, others have shown how consumers themselves see their choices as
informed decisions to undergo experimental interventions rather than perceiv-
ing themselves to be unﬁrmed. These choices are reached by weighing risks
against possible beneﬁts and hope that the interventions carry, which suggests
that health consumers’ decision-making might be governed by diﬀerent priori-
ties and logics than those assumed by mainstream evidence-based medicine
(Rachul, 2011; Chen and Gottweis, 2013; Mazanderani et al., 2017).
As Sleeboom-Faulkner (2015, p. 1) has also suggested, then, there is a need to
‘look beyond regulatory exteriors’ and towards the ‘cultural and socio-political
context of debates on regulation’ of experimental stem cell therapies. This is
so especially because the digitally mediated discursive space around them is
characterised by competing agendas and truth claims about stem cells’ value
and potential. These characteristics are not restricted to the discursive space
around stem cell therapies but exemplify broader trends around the intersection
of new biotechnologies and digital media: debates around anticipatory govern-
ance of commercial genomics, for example, have also assumed polarised ten-
dencies where consumer protectionism is pitted against consumer
empowerment (Prainsack et al., 2008). The experimental stem cell therapy
market and related disputes highlight how orthodox forms of medical and
healthcare provision and governance can be and are challenged by consumers’
and service providers’ agency enacted online.
Methodology
To our knowledge, the only existing documentation of commercial UK-based
stem cell therapy providers was produced by Berger et al. (2016) as part of
their study on the global distribution of DTC stem cell therapy businesses.
They identiﬁed 12 websites of UK-based businesses, but do not provide URLs.
While our primary focus was qualitative thematic analysis of UK businesses’
websites, we thus ﬁrst needed to identify the businesses.
We based our approach on Turner and Knoepﬂer’s (2016) study on DTC
online marketing of stem cell therapies in the USA. We conducted a total of
50 Google search engine key word searches, using terms including ‘stem cell
treatment,’ ‘stem cell therapy,’ and ‘stem cell clinic’ usually combined with the
regional identiﬁer ‘UK.’ We also searched for stem cell types (e.g. ‘adipose’),
speciﬁc medical conditions (e.g. ‘multiple sclerosis’) and ﬁelds of specialisation
(e.g. ‘orthopaedic’). Many businesses were identiﬁed by examining advertise-
ments that accompanied search terms. For each term, we initially reviewed
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10–15 pages of search results unless less than 10 pages were retrieved. Later, we
reviewed between 7–10 pages as new searches decreasingly retrieved new
businesses. We completed data collection when our searches no longer retrieved
new businesses.
The internet searches were conducted in February and March 2018, making
our study a snapshot of UK businesses operational at that time. We aimed to
identify commercial UK businesses advertising experimental stem cell therapies
directly to consumers in exchange for payment. We consequently excluded not-
for-proﬁt clinical trials3 and NHS-aﬃliated clinics oﬀering stem cell therapies
according to NHS procedures, because we took the NHS as key UK authority
in delineating the scope of legitimate(d) therapies. However, we included
private businesses advertising the same stem cell therapies as the NHS, but
with more lenient eligibility criteria. Regulatory compliance was not an
inclusion/exclusion criterion, and our ﬁndings cannot be used to assess this
factor, nor do we make empirical claims about the eﬃcacy or safety of the exper-
imental therapies.
Some businesses based outside the UK had oﬃces but not treatment facilities
in the UK, and we only included businesses advertising stem cell interventions
delivered in the UK. We also excluded businesses advertising (only) mail-order
stem cell products (e.g. cosmetics); research organisations and companies not
oﬀering therapies directly; veterinary businesses; and stem cell biobanks (e.g.
cord blood and tooth).
Websites of businesses meeting our inclusion criteria were downloaded using
the SiteSucker application. Information including the business’ name, website
URL and preliminary website content (e.g. kinds of therapies oﬀered) were
entered into a dataset. We also documented the location and number of individ-
ual facilities operated, as many businesses had a single website but multiple
locations across the UK administering stem cell therapies. We produced two
maps to visualise this data using the Google MyMaps tool, assigning each indi-
vidual facility with a pin.
We then conducted qualitative thematic analysis (see Braun and Clarke, 2006)
of all websites, aiming to identify and examine patters in the semantic content of
thewebsite and the underlying ideas anddiscourses that foreground and shape the
semantic content. This analysis was used to derive key themes, whichwe discuss in
this paper. Inmost cases we only analysed the subpages our search terms retrieved
and the home and ‘about us’ pages to foster a manageable dataset, except when
initial analysis indicated that stem cell- and related therapies where the business’
core focus. In these cases, we analysed the whole website.4
Existing studies undertaking similar mapping eﬀorts and quantitative website
content analyses of commercial stem cell businesses (Berger et al., 2016; Turner
and Knoepﬂer, 2016) have used coding approaches with pre-deﬁned categories
(e.g. of stem cell types or medical specialities, like ‘adipose’ and ‘orthopaedic’).
We did not follow this approach, because we aimed to analyse the language
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used and underlying contexts in which the notion of stem cells was mobilised.
This is why we applied qualitative thematic analysis enabling an in-depth,
‘rich’ account of the data without presuming pre-existing conceptual or theoreti-
cal commitments (Braun and Clarke, 2006). Indeed, UK businesses mobilised
multiple and inconsistent terms, ideas and values to describe the purported
stem cell therapies oﬀered.
Following Turner and Knoepﬂer (2016), we aimed to mitigate the Google
page ranking bias by reviewing up to 15 results pages, but it is probable that
we missed some businesses using marketing phrases diﬀerent from the key
words we used. By restricting the analysis on the subpages, home and ‘about
us’ pages for most websites, it is also possible that we missed relevant infor-
mation provided elsewhere on the websites.
Mapping the UK Stem Cell Therapy Market
We identiﬁed 71 websites of businesses marketing purported stem cell therapies
online directly to consumers and 106 individual facilities across the UK where
the therapies are administered. Notably, these numbers signiﬁcantly diﬀer
from the 12 UK businesses identiﬁed by Berger et al. (2016) perhaps partly
due to diﬀerent search strategies and inclusion criteria. The facilities were con-
centrated in larger cities, with London hosting by far the highest number of
facilities. 28 were clustered in the London West End areas of Marylebone,
Covent Garden, and Fitzrovia which have an association with wealth and
private healthcare (Rappaport, 2000). 15 facilities were located on Harley
Street alone, which is well-known as an epicentre of elite healthcare and medi-
cine that also has a history of attracting criticism focused around concerns over
questionable scientiﬁc integrity and ‘bogus doctors’ (Humphrey, 2004). Indeed,
it has been suggested that Harley Street’s association with alternative medicine
and dubious practices provides an ideological focus of distaste for orthodox
medical practitioners: Harley Street constitutes a useful ‘other’ for orthodox
medicine to unite against (Humphrey, 2004) (Figures 1 and 2).
Most businesses across the UK use the stem cell therapy label in marketing
therapies based onwhat are called adipose or fat stem cells (20 businesses). Thera-
pies based on cells frombonemarrow (13) and blood (8)were also common, some
advertising both. Plant stem cells (4), ‘placenta’ and ‘umbilical cord’ tissue-
derived stem cells ‘harvested from sheep’ (2) and ‘autologous corneal limbal
stem cells’ (1) were also marketed. Many businesses (25) did not specify the bio-
logical origins of stem cells, but made generic claims about stem cell therapy or
treatment, or therapies claimed to promote or rely on stem cells. Several
businesses (12) marketed stem cell therapies using proprietary technologies
with labels such as ‘Lipogems’ or ‘FAMI,’ where the technologies were key to
the marketing strategy. Emphasis on trademarked technologies was a notable
characteristic overall in how the therapies were framed for consumers.
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Corresponding with Turner and Knoepﬂer’s (2016) ﬁndings in the USA,
many UK businesses advertise Platelet Rich Plasma (PRP) therapies as a form
of stem cell or stem cell-based therapy. PRP is a portion of the plasma fraction
in autologous blood that has a high platelet concentration (Marx, 2001) and PRP
therapy generally involves injecting this into an area of the body to promote
tissue repair. Many businesses market PRP therapy by making claims to the
ability of PRP injections to incite or promote stem cell action. While Turner
and Knoepﬂer’s study excludes businesses only marketing PRP therapies, we
included them if PRP was framed as stem cell therapy, or if they made claims
to stem cells as part of the marketing strategy (17 businesses used this approach).
Figure 1. Map of UK stem cell clinics.
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While stem cell therapies were marketed for myriad conditions and ailments,
aesthetic and what can be classed as orthopaedic interventions involving muscu-
loskeletal issues were most common. Many advertised therapies for both muscu-
loskeletal and aesthetic ailments or other combinations of speciality and
procedures in ways that muddied conventional distinctions between cosmetic
and medical interventions. Most commonly advertised were interventions
usually deﬁned as cosmetic (often marketed in combination with other thera-
pies) (52). Musculoskeletal conditions and related pain management were also
common (15). Other therapies included so-called sexual dysfunction, eye con-
ditions, and cancers.
While the number of UK businesses we identiﬁed signiﬁcantly diﬀers from
Berger et al. (2016) ﬁndings, much of our data corresponds to their study on
the global market. They also found that stem cell interventions were most com-
monly marketed for aesthetic factors, with several websites advertising stem cell
therapies for multiple seemingly unrelated conditions. Stem cell therapies for
Figure 2. Map of London stem cell clinics.
12 S. ERIKAINEN ET AL.
conditions beyond the strictly medical (i.e. aesthetic, cosmetic) evidently occupy
a signiﬁcant portion of the market in the UK and beyond.
Regeneration and Rejuvenation
The overarching interpretive framework that UK businesses mobilise in market-
ing experimental stem cell therapies harnesses and commercially re-frames bio-
medical models of ‘regenerative medicine.’ Stem cell therapies are primarily
marketed as a form of ‘regenerative’ or ‘rejuvenation’ therapy, whereby the
regeneration and rejuvenation concepts are used to make comprehensible as
well as to advertise stem cells’ potential. The Centre for Advanced Facial Cos-
metic and Plastic Surgeries (2018) represents this potential as follows:
the principle [is] to use your own body’s natural reparative and healing mechanisms
… In the future [treatments] may be driven by triggering natural reparative mechan-
isms in the body that are able to regenerate and repair themselves, this is the basis of
Stem-Cell based therapy and Regenerative Medicine.
The SW11 clinic (2018) states that ‘Stem cells have the ability to self-renew or
multiply, meaning that they can repair and replace tissue in the human body.
In other words, stem cells have the power to heal.’
The regeneration and rejuvenation concepts in this context derive from and
are intertwined with broader discourses around regenerative medicine and its
potential. Regenerative medicine is an area of translational medical research
drawing from biological theories of cell and tissue generativity, and potential
for restoration of function and performance. As Kent (2012) argues, regenerative
medicine builds on models of the body as regenerative including capacity for
self-renewal. Self-renewal implies not just sexual reproduction, but also ‘autoge-
neration,’ where the role of biomedical intervention is to stimulate or control
this process. Biomedical models around regenerative medicine build on
broader naturalistic interpretations of bodily processes (including disease) that
conceptualise the body as a natural entity that is also plastic or malleable, and
therefore subjected to re-programming (Kent, 2012).
These models for interpreting bodily processes have been adopted but also re-
framed by commercial businesses that use the regeneration and rejuvenation
concepts to make sense of the stem cells therapies they advertise. The businesses
also draw from popular discourses around translational stem cell science and
construct promissory depictions of them. These depictions represent stem
cells as miraculous or futuristic medical actors carrying extraordinary healing
capacity. The eﬀect is a discursive destabilisation of conventional boundaries
of medicine and established medical categories, which is intertwined with rep-
resentations of stem cells as having almost magical properties that collapse
clear divisions between science and mythology (see also Faulkner et al., 2017).
These destabilisations take place in two overlapping ways, which are connected
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with the businesses operating at the intersection of medicine and consumer
culture. Firstly, the businesses are multidisciplinary and merge conventionally
separate areas of medical specialisation. Secondly, they assemble conventionally
distinct medical and aesthetic conditions with seemingly unrelated aetiologies
under the single treatment umbrella of regenerative therapy.
Illustrative are two clinics that operate in partnership in shared facilities on
London Harley Street but have separate (albeit linked) websites and separate
but overlapping clinical teams: The Regenerative Clinic (2018a) and the Regen-
erative Beauty Clinic (2018). Both market their services under the regenerative
therapy umbrella, which collates a variety of conditions and body areas that
are treated. These range from musculoskeletal conditions treated at the Regen-
erative Clinic to aesthetic concerns treated at the Regenerative Beauty Clinic.
The clinics’ primary method of therapy is trademarked Lipogems. It is marketed
as ‘adipose stem cell’ therapy enabling stem cells ‘taken from your own fatty
tissue, to be injected directly into sites of tissue damage, so boosting their
local presence and aiding recovery.’ While the Regenerative Clinic advertises
Lipogems to treat ‘problems aﬀecting the tendons, ligaments, joints and
muscles,’ the Regenerative Beauty Clinic advertises the same technique for aes-
thetic complaints including wrinkles, broader ‘facial rejuvenation,’ and age-
related ‘restoration of facial features.’
The overlap and shared conceptual basis between the two clinics demonstrate
how the idea of regeneration is used as an interpretive frame that clusters see-
mingly disconnected bodily conditions under a single therapeutic paradigm, pro-
viding an alternative to conventional scientiﬁc medical practice. By marketing
Lipogems as a therapeutic solution to myriad musculoskeletal and aesthetic pro-
blems, the clinics shift the epistemological and diagnostic emphasis in medicine
from the conventional specialisation around an object of investigation (e.g. ortho-
paedics, specialising in musculoskeletal conditions). They direct it, instead,
towards regeneration as an epistemological and methodological framework that
takes primacy over the causal origin andmaterial location of the problem treated.
The centring of regeneration and rejuvenation and displacement of clinical
areas and conditions of specialisation is further highlighted in the naming of
businesses using this framework. In addition to the Regenerative- and Regenera-
tive Beauty Clinics, UK-based businesses operate under names including the
Rejuvenation Clinic (2018), Dynamic Regenerative Medicine (2015), Welsh
Cell Therapy Clinic (2018), and London FAMI Clinic (2018), where FAMI
(like Lipogems) is the name of the stem cell administration technique.
The collapse between seemingly unrelated medical and aesthetic complaints is
also exempliﬁed by various multi-sited, combined interventions that are mar-
keted. The Regenerative Clinic website notes that:
Some patients who have Lipogems treatment for joint rejuvenation opt to use some of
the additional fat harvested for facial rejuvenation. This treatment can be done at the
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same time (in one procedure) and allows patients to utilise all the harvested and treated
fat.
Additionally, ‘some patients may opt to have more liposuction performed for
aesthetic reason.’ This suggests that a customer may choose both liposuction
through which stem cells are also harvested, combined with stem cell therapy
using the stem cells simultaneously to treat musculoskeletal conditions and aes-
thetic complaints.
Many businesses make an extraordinary range of claims about the power of
stem cells, which are said to promote eﬀects far beyond the primary purpose
for which they are administered. Vitamin Injections London (2017), for
example, advertises ‘Stemcellation injections’ for anti-ageing based on sheep pla-
centa-derived stem cells. It states that in addition to:
generating a rejuvenated complexion, Stemcellation injections have a range of health-
related beneﬁts. Stem cell injections remedy fatigue and lessen age-related health pro-
blems such as high blood pressure, diabetes, hypertension, cholesterol, gastric ulcers,
migraine, blood circulation disorders and arthritis.
Such representations not only position stem cells as multi-site medico-aesthetic
actors capable of healing all ills but also represent them as having almost magical
properties that can bring about ‘the miracle of rejuvenation’ (Amar Clinic, 2018).
The appeal of regeneration and rejuvenation is intertwined with claims about
stem cells that blur contemporary science, science ﬁction, and mythology. Most
notable in this regard are the Genesis Clinics (2018), which market ‘stem cell
facelifts’ that are claimed to:
harnesses the very life force of the universe in the form of your very own Stem Cells.
Harvested, processed and concentrated into a powerful serum we call ‘Genesis Serum’
we then inject and infuse your face with up to 20 million omnipotent little builders that
go to work instantly rebuilding the tissue from the inside out with new, younger cells.
Mirroring how the regeneration concept is used to cluster various therapies, the
Genesis Clinics mobilise the ‘genesis’ notion to collate myriad women’s health
services. These include, in addition to stem cell facelifts, aesthetic services like
‘body sculpting’ combined with conventional and unconventional sexual and
reproductive health services like coil ﬁtting alongside ‘vaginal rejuvenation’
therapies. Especially in the context of women’s health, the genesis notion asso-
ciatively links the therapies with cultural ‘origin’ narratives. It taps into gendered
conceptualisations of women’s bodies as the source of life because of women’s
reproductive role, which is often culturally perceived to be the creation of life.
By naming the clinics the Genesis Clinics and the stem cell serum they
market as the genesis serum, the business constitutes women’s bodies as the
source of life not only via sexual reproduction but also via autogeneration.
Genesis additionally connotes mythological narratives of the origin of life by
constructing an association between the therapies and biblical genesis narratives
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of divine creation. In relation to the genesis serum, this is the very ‘life force of
the universe’ contained within (women’s) bodies in the form of stem cells.
The above highlights how science and (consumer) culture are being blurred in
the marketing of stem cell therapies. The businesses forge a marketing space for
stem cell therapies as a desirable biomedical lifestyle product (Saukko et al.,
2010) by combining traditionally separated medical and aesthetic interventions
as well as mythological, science ﬁction-like and other cultural tropes to represent
stem cells’ healing power. While commercial businesses build on the science of
regenerative medicine to market their products, the boundaries of what this
science entails are being re-conﬁgured. This is done via future-oriented, promis-
sory uses of science with representations of stem cells as almost omnipotent in
their regenerative potential. These boundaries are also being stretched and the
science of regenerative medicine commercially co-opted to accommodate (and
sell to consumers) powerful cultural aspirations for medicine as regeneration
that heals and simultaneously beautiﬁes.
Age Reversal
A substantial portion of the UK stem cell therapy market is focused on anti-
ageing, which is aimed at achieving an aesthetically desirable youthful appear-
ance. The anti-ageing uses draw from the regeneration and rejuvenation frame-
works but also harness the intertwined idea of ‘reversal’ around ageing. Many
businesses market stem cell anti-ageing therapies in ways that attribute stem
cells with the ability to reverse undesirable ageing processes, represented as
bodily ‘deterioration.’ These representations are linked with broader cultural dis-
courses that frame ageing as a (societal and individual) problem for which new
biotechnologies can oﬀer a solution (Moreira, 2017). The Amar Clinic (2018) for
example claims that their FAMI stem cell therapies are ‘capable of repairing the
damage time has caused in the face’ by ‘restoring some of the underlying defects
that are responsible for the appearance of aging’ and thus ‘restoring the facial
structure to a more youthful state.’ The Pevonia medispa (2017) on the other
hand proclaims that stem cells are ‘the ultimate answer to age-reversal.’
Portrayals of stem cells’ age reversing properties tap into representations of
stem cells as a miraculous creative force, but additionally depict them as the
fountain of youth (see also Rachul et al., 2015). Many businesses make reference
to turning back time or repairing what is represented as damage caused by time,
which represents time as a linear degenerative process moving progressively
from a youthful state of health and beauty towards a damaged state of old
age. This representation is signiﬁcantly gendered: most anti-ageing stem cell
therapies are targeted at women and foregrounded by the broader socio-cultural
naturalisation of youthful femininity as the norm of female embodiment. The
gendered normativity of youth and beauty, in turn, depicts the signs of ageing
as damage to the natural state of womanhood and femininity, which is presumed
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to be young. This gendered dynamic has been well-analysed by others, especially
in relation to the medicalisation of menopause as deterioration requiring treat-
ment (Bell, 1987; Meyer, 2001; Roberts, 2007).
These discourses around stem cell therapies translate to representations of
ageing as progressive deterioration that can now be reversed with stem cells.
While anti-ageing therapies are disproportionately targeted at women, several
related hair restoration therapies are also targeted at men. They are marketed
via similar temporal representations of decline and reversal: ‘if you are in the
early stages of hair loss and you’d like to turn back time,… help is at hand.
We can’t quite build a time machine for you, but we can reverse the early
stages of hair loss’ (Belvedere, 2018).
Many businesses market stem cell anti-ageing therapies by reproducing wider
discourses of ageing as a treatable condition in ways that muddle clear distinc-
tions between medical and aesthetic interventions. They also build on emerging
models of ‘preventative medicine’ and health ‘management’ (rather than treat-
ment) that position health as something that can be acted on proactively. This
includes by individuals themselves who can become agentic in managing their
own health (e.g. Hood and Flores, 2012). Tunc Tiryaki Clinic’s (2017) advertise-
ment for facial stem cell injections, for example, states:
Ageing… is a descent of the whole facial structure.… Facial tissues, similar to all tissues,
decline, weaken and grow old during the process of ageing.… Stem cell treatment
resolves the tissue loss and anatomic deformations of ageing and rejuvenates the face.
The visible signs of ageing are represented as a symptom that results from an
underlying degeneration process, which can be reversed or at least managed
via stem cell therapy. Indeed, the Genesis Clinics among others make reference
to the importance of individuals’ ‘age management regimes’ through which
degeneration is replaced with regeneration.
Stem cell age reversal is exemplary of the emergence of biomedical lifestyle
products occupying a hybrid space between biomedicine and consumer
culture (Saukko et al., 2010). While stem cell businesses build on medical
(ised) models of ageing in particular, they re-frame these models around the
demands of beauty culture in ways that re-conﬁgure these models by positioning
stem cells as the answer to both medical and aesthetic problems of age. They do
this, not only by harnessing powerful cultural tropes around the fountain of
youth, but also by narrating a promise of a better, healthier and more beautiful
future for those who buy into these tropes both ﬁnancially and discursively.
‘Stem Cells are Perhaps Nature’s Best Kept Secret:’ Promissory
Narratives
As other have also argued (Petersen and Seear, 2011), stem cell therapy
businesses use marketing strategies that build on the future-oriented nature of
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discourses around translational stem cell research in particular. This is done in
ways that are intertwined with appeals to stem cell therapies’ ‘naturalness.’ The
promissory scientiﬁc progress narratives that businesses capitalise on are similar
those that have tended to characterise biomedical innovation more generally
(Brown et al., 2000). Businesses use marketing phrases such as ‘cutting-edge’
and ‘ground-breaking’ to describe stem cell interventions, with the Genesis
Clinics (2018) proclaiming that ‘a new era of regenerative medicine is here
and we are at the leading edge.’ Plastic surgeon Dr Bernard Hayot’s website
(2017) not only asserts that ‘stem cell fat transfers’ are the ‘medicine of the
future,’ but also represents the experimental nature of the interventions as
part of their appeal. The website states that the ‘mechanisms of this tissue regen-
eration are still poorly understood and are the subject of many research works
making these techniques of regenerative medicine even more exciting.’
Such framing stands in direct opposition to the critiques from mainstream
medical authorities, who tend to position experimental stem cell therapies as
exploitative and potentially dangerous due to the experimental state. By contrast,
Hayot’s website represents the experimental stage as an exciting and promising
period in ways that rconceptualise the therapies as tentative or in-formation
(Saukko, 2018), and therefore appealing. In so doing, the website deploys a
future-oriented rhetoric where scientiﬁc experimentation is justiﬁed by the
promise of new (and better) treatments (Moreira and Palladino, 2005). Consu-
mers can position themselves as frontrunners of science who can contribute to
scientiﬁc progress by investing in and undergoing promising new, even if exper-
imental, medical interventions. The promissory depictions of stem cell therapy
promoted by commercial businesses are more generally intertwined with mar-
keting strategies that displace possible safety and eﬃcacy concerns around
experimental therapies. They highlight, instead, the promise this experimen-
tation carries in relation to a new era of regenerative medicine, and consumers
are given the opportunity to be a part of realising this new era.
By distinguishing the newness of stem cell-based interventions from previous
approaches (which are in turn represented as increasingly anachronistic), com-
mercial businesses position translational stem cell science and derived therapies
temporally into the future. This has also characterised other new biomedical
technologies (see Powell et al., 2007). The regenerative and rejuvenating
nature of stem cell therapies is distinguished from traditional surgical pro-
cedures which are represented as unnecessarily invasive and belonging, increas-
ingly, into the past. For example, ‘orthopaedic specialist’ Charles Willis-Owen’s
website (2018) contrasts the ‘amazing healing potential’ of a single stem cell
injection against ‘old-fashioned techniques’ requiring multiple operations
including ‘open surgery and a long and protracted recovery.’ Similarly, the
Amar Clinic (2018) compares ‘the traditional face lift [which] beautiﬁes, but it
does not rejuvenate’ with stem cell injections: after undergoing such injections,
‘the patient’s face progressively rejuvenates itself, without the need of surgery.’
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The clinic adds that ‘stem cells are the base of modern rejuvenation procedures,
replacing facelifting.’
The temporal promissory narratives that stem cell therapy businesses put
forward are also intertwined with customer testimonials. These testimonials
document positive improvement after stem cell therapy, often accompanied
with ‘before and after’ imagines that construct transformation stories from an
unhappy before state to a happy after state. Transformation narratives are com-
monly used for cosmetic interventions (Jones, 2008) and aesthetic stem cell
therapies are no exception. Indeed, before and after images and testimonials
also occur for orthopaedic stem cell interventions, showing a diseased bone or
cartilage that has purportedly been regenerated. These narratives, together
with the progress and promise narratives, additionally reinforce the image
that stem cell therapies enable a brighter future for those who invest in it.
Relatedly, many businesses advertise stem cell therapies by distinguishing tra-
ditional surgical interventions from purportedly natural stem cell therapies,
based on the body’s own rejuvenating potential. We identiﬁed ﬁve clinics all
using the phrase ‘stem cells are perhaps nature’s best kept secret.’ While stem
cell therapies are represented as capable of naturally rejuvenating the body
from within, ‘surgery only corrects the wrapping… but does not restore the
items below’ (Amar Clinic, 2018). Representing stem cell therapies as natural
alternatives to surgery also positions surgical interventions as potentially artiﬁ-
cial (in binary opposition to natural) and the naturalness is additionally used to
mitigate possible concerns over the interventions’ safety. Many businesses claim
that the fact that stem cells are natural, originating within the customer’s own
body, alleviates concerns over, or even ensures, their safety.
The notion of naturalness is also used in ways that muddle conventional dis-
tinctions between orthodox and alternative medicine, and medical and alterna-
tive therapies. Many businesses oﬀer therapies (stem cell-based and otherwise)
covering a wide range between well-established medical treatments and entirely
un-evidenced alternative therapies, marketed based on claims about the thera-
pies’ naturalness and future potential. The Regenerative Clinic (2018b), for
example, oﬀers PRP- and shockwave therapy (using ‘acoustic waves’ carrying
‘high energy’ through the body) in addition to stem cell therapies. All are mar-
keted by appealing to ‘the body’s inherent capacity to heal itself.’ Together with
regeneration and rejuvenation, naturalness collates stem cell-based and other
therapies in ways that produces an alternative framework for understanding
what therapy or treatment can amount to. I.e. harnessing natural regeneration
from the body itself rather than administering interventions surgically or with
conventional pharmaceutical solutions (from the outside of the body).
Yet, some clinics simultaneously sit at the borders between conventional and
alternative medicine or merge them to construct hybrid models between con-
ventional and alterative practice, including the Regenerative Clinic. It claims
to ‘specialise in avoiding surgery whenever possible’ and states that regenerative
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therapies can be ‘an appropriate medical alternative to orthopaedic surgery.’
However, it also oﬀers traditional surgical techniques and the website even
includes an educational video about evidence-based medicine.
Future-oriented promissory narratives allow businesses to present themselves
as being at the forefront of biomedicine, enabling health consumers to be part of
realising a new science of regenerative healing in-formation. They also allow
businesses to position themselves as alternative to conventional medical and
healthcare services that is both natural and promotes scientiﬁc advancement,
including via experimental but promising new therapies.
Conclusion
DTC marketing of experimental stem cell therapies has been considered as
mainly a problem of safety and eﬃcacy due to the therapies’ experimental
nature, but the proliferation of these therapies should also be analysed in the
broader context in which the therapies have been commercialised and promoted
as beneﬁcial. We have therefore explored how stem cells are represented to con-
sumers online by DTC businesses, especially the underlying epistemic frames
and how they ﬁt within the current landscape of science, medicine, and consu-
mer culture.
Our analysis of the digitally mediated experimental stem cell therapy market
in the UK shows that the boundaries around and between science and consumer
culture are being re-conﬁgured. This is happening via the blurring of conven-
tionally separate medical specialisations, distinctions between medical and cos-
metics therapies and conventional and alternative medicine as well as between
science, science ﬁction, and mythology. The epistemological and interpretative
framework of regeneration and rejuvenation shifts the emphasis and causal
chain of medical practice from sub-specialities and identifying aetiologies
towards the single umbrella of regenerative or rejuvenation therapy. The uses
of the notion of reversal in turn intertwine medical(ised) models of ageing
with the demands of youth-centred commercial beauty culture.
These frameworks for conceptualising stem cell therapies are central to how
their potential is represented and marketed to consumers. They are embedded
within the emergence of biomedical lifestyle products that are ambiguously situ-
ated in relation to medical and consumer goods (Saukko et al., 2010). The emer-
gence of these products, in turn, is part of broader digital era trends towards
knowledge pluralism and (health) consumer agency enacted online, which is
facilitating the proliferation of alternative interpretations and practices of medi-
cine and health (Neﬀ and Nafus, 2016; Saukko, 2018). It is also contributing to
the re-drawing of conventional boundaries around science and medicine
(Nowotny et al., 2001; Saukko et al., 2010).
Stem cell therapies are also, and relatedly, marketed via promissory narratives
(Brown et al., 2000). These concern a new kind of natural, non-invasive
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regenerative medicine of the future, which is in the process of emerging via
translational stem cell science to which health consumers can participate.
Viewed through this lens, the experimental nature of the therapies appears to
be an exciting period of possibilities and promise (rather than dangerous or
suspect due to the therapies’ unproven nature). This is precisely because the
therapies are tentative, and because translational regenerative medicine is still
in its formative stages, which enables health consumers to be positioned as con-
tributors to the realisation of a medical transformation. According to stem cell
therapy businesses, the transformation can be achieved, among other things,
by investing in experimental stem cell therapies.
The DTC stem cell therapy market primarily exists in digital spaces where
businesses can freely distribute promotional content that oﬀers alternative rep-
resentations of what stem cells science can accomplish. Consumers can directly
access content, interact with commercial sources, service providers, and content
created by other consumers. They must, however, simultaneously navigate the
often conﬂicting and even contradictory information provided by conventional
healthcare providers and authorities promoting evidence-based medical stan-
dards. The consequence is a complex web of digitally mediated knowledge
claims and discourses at the same time as market actors (from service providers
to consumers) are increasingly agentic in interpreting and prioritising the value
of competing epistemic models and therapy options. To gain people’s attention
and trust, conventional service providers must compete with commercial
businesses oﬀering alternative options and ways to imagine the present and
future of stem cell medicine.
The DTC stem cell therapy market exempliﬁes broader shifts in how com-
mercial businesses and consumers are changing medical practices and re-
drawing the boundaries of medicine itself via market logics and digital agency.
The discursive and epistemic frames that businesses use build on and commer-
cially harness broader cultural ideas and aspirations to construct powerful,
appealing visions of what (regenerative) science could be(come). They
promise something new and better to for health consumer to invest in.
It is consequently not suﬃcient to presume the value of evidence-based bio-
medicine in delineating what the problem around experimental stem cell thera-
pies actually is. Indeed, how we delineate and frame the problem shapes the
kinds of responses that are developed to address it. We must also look beyond
issues of safety, eﬃcacy, etc. towards the digitally mediated discursive and epis-
temic contexts in which these therapies have proliferated to understand and
appropriately respond to them. As Marres (2018, p. 441) has argued, in
‘today’s dynamic and diverse public spheres, epistemic authority will… have
to be earned the hard way, through an exchange between epistemically diverse
viewpoints.’ It is only by accounting for this diversity that we can begin to
assess how we can or should respond to alternative commercial healthcare
including experimental stem cell therapies.
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Notes
1. ‘Healthcare provider’ here broadly means public, private, licensed, and un-licensed
individuals and organisation providing healthcare.
2. Notable exception is Rachul et al. (2015).
3. We identiﬁed no pay-to-participate clinical trials.
4. This was the case for six clinics: Regenerative Clinic, Regenerative Beauty Clinic, Welsh
Cell Therapy Clinic, London FAMI Clinic, Kerastem, and Dynamic Regenerative
Medicine.
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